Analyst Bullish On SQZ Biotech’s Technology For Solving Cell Therapy Challenges
HC Wainwright initiated coverage on SQZ Biotechnologies Company (NYSE:SQZ) with a Buy rating and a price target of $10. SQZ is focused…
HC Wainwright Starts Coverage on This Small-Cap Cancer Focused Stock
HC Wainwright initiated coverage on Tango Therapeutics Inc (NASDAQ:TNGX) with a Buy rating and a price target of $10 per share. Tango…
HC Wainwright Says Talaris’ Technology Unprecedented In Cell Therapy Space
HC Wainwright initiated coverage on Talaris Therapeutics Inc (NASDAQ:TALS) with a Buy rating and a price target of $18. Talaris leverages its…
UBS Initiates Coverage On Vtex with Neutral Rating, Announces Price Target of $4.3
UBS initiates coverage on Vtex (NYSE:VTEX) with a Neutral rating and announces Price Target of $4.3.
UBS Initiates Coverage On National Instruments with Neutral Rating, Announces Price Target of $43
UBS analyst Damian Karas initiates coverage on National Instruments (NASDAQ:NATI) with a Neutral rating and announces Price Target of $43.
B of A Securities Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $39
B of A Securities analyst Tazeen Ahmad initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy rating and announces Price Target of $39.
Argus Research Initiates Coverage On Overstock.com with Hold Rating
Argus Research analyst Kristina Ruggeri initiates coverage on Overstock.com (NASDAQ:OSTK) with a Hold rating.
Goldman Sachs Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $174
Goldman Sachs analyst Paul Choi initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $174.
HC Wainwright & Co. Initiates Coverage On SQZ Biotechnologies with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on SQZ Biotechnologies (NYSE:SQZ) with a Buy rating and announces Price Target of $10.
HC Wainwright & Co. Initiates Coverage On Tango Therapeutics with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Robert Burns initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Price Target of $10.